TNFSF11 and osteoporosis: In the bone remodeling cycle, a major discovery is the important role of the receptor activator of nuclear factor kappa B ligand (RANKL) in osteoclast formation, and this has prompted the development of monoclonal antibodies that target RANKL for the treatment of osteoporosis.